

Opella.

Date: 11 October 2024

To,

BSE Limited, Corporate Relationship Department, Dalal Street, Mumbai – 400001 Scrip Code: 544250	National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 Symbol: SANOFICONR
--	--

Re.: Disclosure under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“Takeover Regulations”).

Dear Sir / Ma’am,

This is in reference to the prior intimation made by Opella Healthcare Participations BV (“Opella”) to the stock exchanges (namely BSE Limited and National Stock Exchange of India) under Regulation 10(5) of the Takeover Relations on 3 October 2024 informing you about the proposed inter-se transfer of equity shares of Sanofi Consumer Healthcare India Limited (“SCHIL”), between Hoechst GmbH and Sanofi (existing promoters of SCHIL, collectively the “Sellers”) and Opella (“Acquirer”/“Buyer”), to be undertaken in one or more tranches.

In this connection, we now wish to inform you that, we, Opella acquired 1,39,04,722 equity shares in SCHIL (representing 60.37% of the equity share capital of SCHIL) from Hoechst GmbH on 10 October 2024. The said inter-se transfer was undertaken on-market of the BSE Limited stock exchange.

Please find enclosed the disclosure in respect of the aforesaid sale.



For and on behalf of Opella Healthcare Participations B.V

A handwritten signature in blue ink, consisting of stylized, overlapping loops and strokes.

Authorized Signatory

Name: Peter Brouwer

Designation: Director

Date: 11 October 2024

Place: Amsterdam, the Netherlands

Opella.

Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part A – Details of the Acquisition

Name of the Target Company (“TC”)	Sanofi Consumer Healthcare India Limited		
Name(s) of the acquirer and Persons Acting in Concert (“PACs”) with the acquirer	Opella Healthcare Participations B.V.		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Limited and BSE Limited.		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	0	0%	0%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
c) Voting rights (“VR”) otherwise than by equity shares	0	0%	0%
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	0	0%	0%
e) Total (a+b+c+d)	0	0%	0%
Details of acquisition			
a) Shares carrying voting rights acquired	1,39,04,722	60.37%	60.37%
b) VRs acquired otherwise than by equity shares	N.A.	N.A.	N.A.
c) Warrants/convertible securities/any other			

Opella.

instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	N.A.	N.A.	N.A.
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N.A.	N.A.	N.A.
e) Total (a+b+c+/-d)	1,39,04,722	60.37%	60.37%
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	1,39,04,722	60.37%	60.37%
b) VRs otherwise than by equity shares	N.A.	N.A.	N.A.
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	N.A.	N.A.	N.A.
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N.A.	N.A.	N.A.
e) Total (a+b+c+d)	1,39,04,722	60.37%	60.37%
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer / encumbrance, etc).	Inter-se transfer of equity shares (undertaken on-market) which is exempt from making an open offer under Regulation 10(1)(a)(iii) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Equity shares carrying voting rights.		
Date of acquisition of/ date of receipt of intimation of allotment of shares/ VR/ warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares in the TC.	10 October 2024		
Equity share capital / total voting capital of the TC before the said acquisition	2,30,30,622 equity shares (as per the shareholding pattern dated 6 September 2024 that is publicly disclosed by the TC).		

Opella.

Equity share capital / total voting capital of the TC after the said acquisition	2,30,30,622 equity shares (as per the shareholding pattern date 6 September 2024 that is publicly disclosed by the TC).
Total diluted share / voting capital of the TC after the said acquisition	2,30,30,622 equity shares (as per the shareholding pattern dated 6 September 2024 that is publicly disclosed by the TC).

Opella.

Part – B (*)**

Name of the Target Company: Sanofi Consumer Healthcare India Limited

Name of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to the promoter/promoter group	PAN of the acquirer
[REDACTED]	Yes	[REDACTED]

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



For and on behalf of
Opella Healthcare Participations B.V.

)
)
)
)
)
)

Authorised Signatory

Name: Peter Brouwer

Designation: Director

Date: 11 October 2024

Place: Amsterdam, the Netherlands